Data on intraprocedural anticoagulation
The time-course curves of the ACT differed significantly across the
patients with apixaban, dabigatran, edoxaban, and rivaroxaban, and its
highest levels were seen in the dabigatran group during the time period
between the 1st and 4th ACT
measurements (Figure 1). The average ACT was greater in the patients
with dabigatran than in those with the other DAOCs
(312.3±34, 334.4±44, 308.1±41, and
305.8±34.7 sec; P <0.001, Figure 2). Time from the initial
heparin injection to the first achievement of the target ACT differed
significantly across the patient groups (54.8±25.6, 47.2±21.6,
56.1±26.8, and 50.6±24.1 sec; P=0.02), with its shortest time in the
dabigatran group (Figure 2). A significant difference was noted in the
total heparin requirement across the patient groups (3990.2±1167.9,
3890.4±955.3, 4423.8±1051.6, and 3972±978.7 U/m2/h; P
<0.001), with its greatest amount in the edoxaban group
(Figure 3).